Pulmonary drug delivery: A promising approach.
Loading...
Date
2012-06
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Pulmonary drug delivery has attracted tremendous scientific and biomedical interest
in recent years and has progressed considerably within the context of local treatment for lung
diseases, by virtue of enhanced local targeting and reduced systemic side effects with the
administration of minute drug dosages. Furthermore, with the high surface area and
permeability of the lung, the 21st century has seen a paradigm shift to inhaled therapy for
systemic use. But the pulmonary tract tends to be considered as very promising and attractive
route for the administration of active substances intended to treat local pulmonary e.g., asthma,
chronic obstructive pulmonary disease (COPD), microbial infections) as well as systemic
diseases. (e.g., diabetes) Recent progress within biotechnology has generated a group of novel
protein and peptide drugs to which administration to the respiratory tract, to obtain systemic
delivery seems advantageous compared to e.g. parenteral or gastrointestinal administration
(tablets, capsules etc.). The low metabolic activity in the lungs allows systemic delivery without
liver passage Hence lung is an attractive environment for biomolecules, which are highly
susceptible to enzymatic degradation in the gastrointestinal tract (ventricle and guts) as well as
hepatic degradation (first pass metabolism).
Description
Keywords
Pulmonary drug delivery, Dry powder for inhalation, Asthma, Chronic obstructive pulmonary disease
Citation
Shah N D, Shah V V, Chivate N D. Pulmonary drug delivery: A promising approach. Journal of Applied Pharmaceutical Science. 2012 June; 2(6): 33-37.